ArticleCureus2025
Pembrolizumab-Induced Aplastic Anemia Successfully Treated With Thrombopoietin Receptor Agonist in a Patient With Lung Adenocarcinoma: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 71-year-old female with postoperative recurrence of lung adenocarcinoma was treated with chemotherapy plus immunotherapy (carboplatin, pemetrexed, and pembrolizumab). On day eight after the first cycle, she presented with fever and loss of appetite. Laboratory tests showed severe pancytopenia. Bone marrow biopsy revealed hypocellular marrow consistent with aplastic anemia (AA), which is considered an immune-related adverse event (irAE). Treatment with pulse glucocorticoid (GC) therapy, granulocyte colony-stimulating factor, and cyclosporine had a limited effect. On day 24, eltrombopag, a thrombopoietin receptor agonist, was started, subsequently leading to gradual hematologic recovery and discharge on day 34. IrAE-induced AA has a poor prognosis, with no established standard treatment. This case demonstrates the potential of thrombopoietin receptor agonists as a therapeutic option in GC-resistant irAE-induced AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.